Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05338970 · ClinicalTrials.gov registry record · Phase 3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer and Egfr L858R, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
- 20
- Study locations
NCT05338970: Active Phase 3 study of Non-squamous Non-small Cell Lung Cancer and Egfr L858R, sponsored by Daiichi Sankyo.
NCT05338970 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer and Egfr L858R that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 586 participants, above the 333-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05338970, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer and Egfr L858R, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
- 20
- Study locations
Study Summary
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
Primary Outcome
Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.
Conditions Studied
Interventions
- DRUG Platinum-based chemotherapy
- DRUG Patritumab Deruxtecan
Study Locations (20)
California
- City of Hope - Duarte
- Moores Cancer Center at the UC San Diego Health - La Jolla
- Scripps MD Anderson Cancer Center - La Jolla
- USC Norris Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Vallejo Medical Center - Vallejo
- Innovative Clinical Research Institute - Whittier
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Alaska
- Alaska Oncology and Hematology LLC - Anchorage
Arkansas
- Highlands Oncology - Springdale
Florida
- Sarah Cannon/Florida Cancer Specialists - FCS South - Port Charlotte
Georgia
- Emory University - Atlanta
Idaho
- St Luke's Cancer Institute - Boise
Maryland
- American Oncology Partners of Maryland - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
What the registry record for NCT05338970 still lists
NCT05338970 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, above the 333-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (76% higher).
The record links to 3 conditions, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Platinum-based chemotherapy is the first listed.
NCT05338970 names 20 study sites across 14 states, led by California, New York, Alaska.
Frequently Asked Questions
What is clinical trial NCT05338970 about?
NCT05338970 is a clinical study titled "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy". Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for ...
What is the current status of trial NCT05338970?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2022-07-08. Estimated completion is 2026-06-30.
What conditions does trial NCT05338970 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer, Egfr L858R, EGFR Exon 19 Deletion.
What interventions are being tested in trial NCT05338970?
The interventions under investigation include: Platinum-based chemotherapy (DRUG), Patritumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05338970?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05338970 being conducted?
This trial has 20 study locations across Alaska, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05338970's enrollment target sits among peer trials
586 3rd of 9 higher than 7 of 9 other Non-squamous Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-squamous Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI